Since publication of the last full practice guideline and guideline watch on schizophrenia, there have been a multitude of studies on new pharmacological and nonpharmacological treatments for schizophrenia.
Short- to intermediate-term exposure to atypical antipsychotic medications may dysregulate adaptive immune responses, increasing susceptibility to respiratory infections like COVID-19.
Researchers conducted a systematic review and meta-analysis to assess the incidence and predictors of psychosis relapse in individuals receiving treatment with antipsychotic agents.
Research was conducted to assess the impact of initiation of treatment with second-generation antipsychotics and treatment interruptions on weight gain in patients with schizophrenia and bipolar 1 disorder.
Untreated stress amongst healthcare professionals can lead to a multitude of issues while prolonged stress can contribute to burnout. In order to ensure the safety of both clinicians and patients, effective and feasible interventions are needed for individuals and organizations.
A recent study aimed to assess the ability of classifiers to identify individuals with schizophrenia, autism spectrum disorder, and typical development based on findings from magnetic resonance imaging.
In a phase 3, double-blind trial, the effect of combined olanzapine and samidorphan treatment compared with treatment with olanzapine alone on the weight profile of patients with schizophrenia was evaluated.
Compared with usual treatment, the use of long-acting injectable antipsychotics significantly increased the time to first hospitalization in patients with early-phase schizophrenia.
